Clayton Dubilier & Rice completed the acquisition of a 50% stake in Opella from Sanofi for €8bn.

Clayton Dubilier & Rice, a global investment firm, completed the acquisition of a 50% stake in Opella, the consumer healthcare unit of Sanofi, an innovative global healthcare company, for €8bn. “We have full confidence in Opella’s future as a new independent champion. Built on the strength of its talented teams, deep consumer understanding, and international reach, Opella is perfectly positioned for long-term success. With the support of CD&R—renowned for its expertise in the consumer and healthcare sectors and its commitment to people, communities, and sustainability, Opella is ready to grow and thrive. This new chapter marks the beginning of a promising journey for a company we believe in deeply," Paul Hudson, Sanofi CEO.